Fig. 2From: Antibody targeting of claudin-1 as a potential colorectal cancer therapyDifferential expression and clinical value of CLDN1 gene expression in CRC samples from patients with mCRC. a CLDN1 gene expression in 143 primary CRC samples classified according to the five molecular subtypes described by Sadanandam et al. [24], the six molecular subtypes described by Marisa et al. [23], the three molecular subtypes described by De Sousa et al. [25], and the four consensus subtypes [26] (Kruskall Wallis/Dunn’s test). b Associations between CLDN1 gene expression level and progression-free survival (PFS) in patients with C3 and C5 subtype tumors (log-rank test). High CLDN1: >median; low CLDN1: <median CLDN1 expression (9.75 arbitrary units)Back to article page